SOPH
SOPHiA GENETICS S.A.NASDAQHealthcare$5.04-1.79%ClosedMarket Cap: $361.2M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
7.17
P/S
4.59
EV/EBITDA
-5.30
DCF Value
$-25.24
FCF Yield
-11.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.4%
Operating Margin
-91.2%
Net Margin
-102.2%
ROE
-117.0%
ROA
-48.3%
ROIC
-61.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $21.7M | $-19.2M | $-0.28 |
| FY 2025 | $77.3M | $-79.0M | $-1.17 |
| Q3 2025 | $19.5M | $-20.0M | $-0.30 |
| Q2 2025 | $18.3M | $-22.4M | $-0.33 |
Analyst Ratings
View AllGuggenheimBuy
2026-01-26BTIGBuy
2025-11-10Trading Activity
Insider Trades
View AllVerma Abhimanyuofficer: Chief Technology Officer
SellFri Apr 03
Camblong Jurgidirector, officer: Chief Executive Officer
SellFri Apr 03
Camblong Jurgidirector, officer: Chief Executive Officer
SellFri Apr 03
Xu Zhenyuofficer: Chief Scientific Officer
SellFri Apr 03
Xu Zhenyuofficer: Chief Scientific Officer
SellFri Apr 03
Company Info
Sector
Healthcare
Industry
—
Country
CH
Exchange
NASDAQ
Beta
1.04
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.